Skip to the guide
EXACT 41

Endocrine research / EDUCATIONAL GUIDE

Tesamorelin

Tesamorelin 20 mg box packaging mockup
Packaging mockup
20 mg€74.90

Research aims, observed effects
and the limits of the evidence.

Specific approved medicine existsSources checked 6 September 2026

THE IDEA IN EVERYDAY TERMS

Excess abdominal fat in a specific condition

Tesamorelin prompts growth-hormone release and raises IGF-1, a hormone involved in growth-related signalling. Its approved use concerns excess abdominal fat in adults with HIV-associated lipodystrophy, a condition involving changes in body-fat distribution. The focus is visceral fat—the fat inside the abdomen around organs.

Read the background ↗

Human evidence for a defined indication

What has actually been shown?

The approved medicine Egrifta SV can reduce excess abdominal fat in that patient group. Its label specifically says it is not for general weight-loss management. Reducing visceral fat in this condition is different from promising visible abs, overall weight loss or better athletic performance. Hormonal effects also bring risks, including elevated IGF-1 and glucose intolerance.

Read the evidence ↗

01 / OVERVIEW

What is Tesamorelin?

Tesamorelin is a growth-hormone-releasing factor analogue. Egrifta SV is an approved medicine containing tesamorelin. [1]

02 / RESEARCH AIMS

Why it is studied.

Its labelled use is reducing excess abdominal fat in adults with HIV-associated lipodystrophy. It is not indicated for general weight-loss management. [1]

03 / RESEARCH MAP

Following the research question.

Tesamorelin stimulates growth hormone production and raises IGF-1. These endocrine effects help explain both its research interest and its safety considerations. [1]

Tesamorelin research map: GHRF analogue; GH / IGF-1 signalling; Defined clinical indicationRESEARCH MAP / TESAMORELIN01GHRF analogue02GH / IGF-1 signalling03Defined clinical indication
Conceptual research map, not a molecular structure or a proven chain of clinical effects. [1]

04 / OBSERVED EFFECTS

What the evidence shows.

Clinical evidence supports a defined indication and formulation. It does not establish general fat-loss, athletic-performance or longevity benefits. [1]

Study context

Human clinical evidence

Key distinction

Specific labelled use

Uncertainty

Broader claims unsupported

A selected-source overview, not a systematic review. Research findings are not verified effects of an independently supplied sample.

05 / SAFETY AND LIMITATIONS

Risks belong beside the findings.

Labelled concerns include elevated IGF-1, fluid retention, glucose intolerance or diabetes, and hypersensitivity. Active malignancy is a contraindication. [1]

Long-term cardiovascular safety has not been established. The approved formulation is not interchangeable with an independently supplied research sample.

06 / REFERENCES

Go to the source.

  1. DailyMed — Egrifta SV prescribing information ↗

    Official product label: indication, mechanism and warnings.